La Lunga Attesa: Towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease

Neuroradiology Journal

Volumn 19, Issue 4, 2006, Pages 453-474

  Villemagne, Victor L ^a,c,d   Ng, S ^a   Cappai, R ^b,c,d   Barnham, K J ^c,d   Fodero Tavoletti, M T ^c,d   Rowe, C C ^a,b   Masters, C L ^c,d  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Alzheimer's disease; A ; Brain imaging; Emission tomography; Magnetic resonance imaging; Neurodegenerative disorders

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLIOQUINOL; CONTRAST MEDIUM; DONEPEZIL; ESTROGEN; GALANTAMINE; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RADIOLIGAND; RIVASTIGMINE; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOSIS; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 33750920107     PISSN: 19714009     EISSN: None     Source Type: Journal    
DOI: 10.1177/197140090601900406     Document Type: Review

References (343)

1. Khachaturian ZS: Diagnosis of Alzheimer's disease. Arch Neurol, 42: 1097-1105, 1985.
2. Isacson O, Seo H, Lin L et Al: Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci, 25: 79-84, 2002.
3. Baudelaire C, Edgar Poe: Sa vie et ses œuvres, in Histoires Extraordinaires par Edgar Poe, Lévy M, Editor, Paris: 1856.
4. Cummings JL, Vinters HV, Cole GM et Al: Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51: S2-17-S65-17, 1998.
5. Larson EB, Edwards JK, O'Meara E et Al: Neuropathologic diagnostic outcomes from a cohort of out-patients with suspected dementia. J Gerontol A Biol Sci Med Sci 51: M313-M318, 1996.
6. Rasmusson DX, Brandt J, Steele C et Al: Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 10: 180-188. 1996.
7. American Psychiatric Association DSM-IV: Diagnostic and statistical manual (Fourth Edition). DSM-IV: Diagnostic and statistical manual (Fourth Edition), Washington. DC: American Psychiatric Association 1994.
8. th edition (ICD-10): classification of mental and behavioural disorders. Geneva, Switzerland: World Health Organization 1992.
9. McKhann G, Drachman D, Folstein M et Al: Clinical Diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944, 1984.
10. Petersen RC, Stevens JC, Ganguli M et Al: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1133-1142. 2001.
11. Petersen RC: Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15: 93-101, 2000.
12. Petersen RC, Smith GE, Waring SC et Al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308, 1999.
13. Petersen RC, Smith GE, Ivnik RJ et Al: Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273: 1274-1278, 1995.
14. rd Edition), Burns A, O'Brien J, and Ames D. Editors Hodder Arnold. London 2005: 393-407.
15. Masters CL, Beyreuther K: The neuropathology of Alzheimer's disease in the year 2005, in Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, Beal MF, Lang AE, and Ludolph AC. Editors Cambridge University Press: Cambridge 2005: 433-440.
16. Jellinger K: Morphology of Alzheimer disease and related disorders, in Alzheimer disease: epidemiology, neuropathology, neurochemistry, and clinics., Maurer K, Riederer P, and Beckmann H, Editors Springer-Verlag 1990: 61-77.
17. Michaelis ML, Dobrowsky RT, Li G: Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 19: 289-293, 2002.
18. Jellinger KA, Bancher C: Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 54: 77-95, 1998.
19. Perl DP: Neuropathology of Alzheimer's disease and related disorders. Neurol Clin 18: 847-864, 2000.
20. nd Edn). London, Arnold 2000.
21. Geula C, Wu CK, Saroff D et Al: Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4: 827-831, 1998.
22. Lu M, Kosik KS: Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell 12: 171-184, 2001.
23. Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250: 279-282, 1990.
24. Lovestone S, Reynolds CH: The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324, 1997.
25. Frank RA, Galasko D, Hampel H et Al: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group: NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24: 521-536, 2003.
26. Geula C: The early diagnosis of Alzheimer's disease, in Pathological diagnosis of Alzheimer's disease, Scinto LFM and K.R. D, Editors. Humana: Totowa, NJ 2000: 65-82.
27. Masters CL, Simms G, Weinman NA et Al: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249, 1985.
28. Cappai R, White AR: Amyloid beta. Int J Biochem Cell Biol 31: 885-889, 1999.
29. Haass C, Koo EH, Mellon A et Al: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357: 500-503, 1992.
30. Seubert P, Vigo-Pelfrey C, Esch F et Al: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359: 325-327, 1992.
31. Shoji M, Golde TE, Ghiso J et Al: Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258: 126-129, 1992.
32. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890, 1984.
33. Harper JD, Lansbury PT Jr: Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407, 1997.
34. Soto C, Castano EM, Frangione B et Al: The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 270: 3063-3067, 1995.
35. Inoue S, Kuroiwa M, Tan R et Al: A high resolution ultrastructural comparison of isolated and in situ murine AA amyloid fibrils. Amyloid 5: 99-110, 1998.
36. Cohen AS, Shirahama T, Skinner M: Electron microscopy of amyloid, in Electron Microscopy of Proteins. Harris JR. Editor. Academic Press, London 1982: 165-205.
37. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 298: 789-791, 2002.
38. Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924: 17-25, 2000.
39. Selkoe DJ, The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin 18: 903-922, 2000.
40. Masters CL, Beyreuther K: Alzheimer's disease. Bmj 316: 446-448, 1998.
41. Masters CL, Beyreuther K: Molecular neuropathology of Alzheimer's disease. Arzneimittelforschung 45: 410-412, 1995.
42. Bartus RT, Emerich DF: Cholinergic markers in Alzheimer disease. Jama 282: 2208-2209, 1999.
43. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
44. rd Edition), Burns A, O'Brien J, and Ames D, Editors Hodder Arnold: London 2005: 426-435.
45. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
46. Westermark P, Benson MD, Buxbaum JN et Al: Amyloid fibril protein nomenclature 2002. Amyloid 9: 197-200, 2002.
47. Stevens FJ, Kisilevsky R: Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 57: 441-449, 2000.
48. Perry EK, Tomlinson BE, Blessed G et Al: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 1457-1459, 1978.
49. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114: 797-811, 1968.
50. Yamaguchi H, Hirai S, Morimatsu M et Al: Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (Berl) 77: 113-119, 1988.
51. Sunderland T, Linker G, Mirza N et Al: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama 289: 2094-2103, 2003.
52. McLean CA, Cherny RA, Fraser FW et Al: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol 46: 860-866, 1999.
53. Mega MS, Chu T, Mazziotta JC et Al: Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport 10: 2911-2917, 1999
54. Greenberg SM, Rebeck GW, Vonsattel JP et Al: Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38: 254-259, 1995.
55. McLean CA, Beyreuther K, Masters CL: Amyloid Abeta levels in Alzheimer's disease. A diagnostic tool and the key to understanding the natural history of Abeta? J Alzheimers Dis 3: 305-312, 2001.
56. Naslund J, Haroutunian V, Mohs R et Al: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 283: 1571-1577, 2000.
57. Lue LF, Kuo YM, Roher AE et Al: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862, 1999.
58. Wang J, Dickson DW, Trojanowski JQ et Al: The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol 158: 328-337, 1999.
59. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron 6: 487-498, 1991.
60. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992.
61. Checler F, Vincent B: Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci 25: 616-620, 2002.
62. Robinson SR, Bishop GM: The search for an amyloid solution. Science 298: 962-964, 2002.
63. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154-159, 1997.
64. Mudher A, Lovestone S: Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26, 2002.
65. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: 23-31, 1999.
66. St George-Hyslop PH: Genetic factors in the genesis of Alzheimer's disease. Ann NY Acad Sci 924: 1-7, 2000.
67. Citron M, Oltersdorf T, Haass C et Al: Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674, 1992.
68. Cai XD, Golde TE, Younkin SG: Release of excess zamyloid beta protein from a mutant amyloid beta protein precursor. Science 259: 514-516, 1993.
69. Suzuki N, Cheung TT, Cai XD et Al: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336-1340, 1994.
70. Citron M, Vigo-Pelfrey C, Teplow DB et Al: Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91: 11993-11997, 1994.
71. Goate A, Chartier-Harlin MC, Mullan M et Al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706, 1991.
72. Rovelet-Lecrux A, Hannequin D, Raux G et Al: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38: 24-26, 2006.
73. Miklossy J, Taddei K, Suva D et Al: Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol Aging 24: 655-662, 2003.
74. Rogaev EI, Sherrington R, Rogaeva EA et Al: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778, 1995.
75. Sherrington R, Rogaev EI, Liang Y et Al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760, 1995.
76. Scheuner D, Eckman C, Jensen M et Al: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870, 1996.
77. Citron M, Westaway D, Xia W et Al: Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72, 1997.
78. Duff K, Eckman C, Zehr C et Al: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713, 1996.
79. Levy-Lahad E, Wasco W, Poorkaj P et Al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977, 1995.
80. Thinakaran G, Teplow DB, Siman R et Al: Metabolism of the "Swedish" amyloid precursor protein variant in neuro 2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J Biol Chem 271: 9390-9397, 1996.
81. Corder EH, Saunders AM, Strittmatter WJ et Al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923, 1993.
82. Poirier J, Davignon J, Bouthillier D et Al: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699, 1993.
83. Strittmatter WJ, Saunders AM, Schmechel D et Al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981, 1993.
84. Borchelt DR, Thinakaran G, Eckman CB et Al: Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013, 1996.
85. Polvikoski T, Sulkava R, Haltia M et Al: Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333: 1242-1247, 1995.
86. Schmechel DE, Saunders AM, Strittmatter WJ et Al: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U SA 90: 9649-9653, 1993.
87. Rebeck GW, Reiter JS, Strickland DK et Al: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11: 575-580, 1993.
88. Hyman BT, West HL, Rebeck GW et Al: Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 92: 3586-3590, 1995.
89. Mehta ND, Refolo LM, Eckman C et Al: Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43: 256-258, 1998.
90. Skovronsky DM, Doms RW, Lee VM: Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol 141: 1031-1039, 1998.
91. Bush AI: The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214, 2003.
92. Haass C, Schlossmacher MG, Hung AY et Al: Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325, 1992.
93. Harkany T, Hortobagyi T, Sasvari M et Al: Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 23: 963-1008, 1999.
94. Harkany T, Abraham I, Konya C et Al: Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 11: 329-382, 2000.
95. Reiter RJ: Oxidative processes and antioxidative defense mechanisms in the aging brain. Faseb J 9: 526-533, 1995.
96. Bush AI: Metals and neuroscience. Curr Opin Chem Biol 4: 184-191, 2000.
97. Huang X, Moir RD, Tanzi RE et Al: Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci 1012: 153-163, 2004.
98. Huang X, Cuajungco MP, Atwood CS et Al: Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 130: 1488S-1492S, 2000.
99. Atwood CS, Huang X, Moir RD et Al: Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst 36: 309-364, 1999.
100. Barnham KJ, Masters CL, Bush AI: Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3: 205-214, 2004.
101. Tomidokoro Y, Ishiguro K, Harigaya Y et Al: Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett 299: 169-172, 2001.
102. Zheng WH, Bastianetto S, Mennicken F et Al: Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115: 201-211, 2002.
103. Parihar MS, Hemnani T: Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11: 456-467, 2004.
104. Drouet B, Pincon-Raymond M, Chambaz J et Al: Molecular basis of Alzheimer's disease. Cell Mol Life Sci 57: 705-715, 2000.
105. Vajda FJ: Neuroprotection and neurodegenerative disease. J Clin Neurosci 9: 4-8, 2002.
106. Saez TE, Pehar M, Vargas M et Al: Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18: 275-280, 2004.
107. Roher AE, Chaney MO, Kuo YM et Al: Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635, 1996.
108. Walsh DM, Klyubin I, Fadeeva JV et Al: Naturally-secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539, 2002.
109. Harper JD, Wong SS, Lieber CM et Al: Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38: 8972-8980, 1999.
110. Pike CJ, Burdick D, Walencewicz AJ et Al: Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687, 1993.
111. Lorenzo A, Yankner BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91: 12243-12247, 1994.
112. Curtain CC, Ali F, Volitakis I et Al: Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem 276: 20466-20473, 2001.
113. Bush AI, Goldstein LE: Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts. Novartis Found. Symp 235: 26-43, 2001.
114. Cuajungco MP, Goldstein LE, Nunomura A et Al: Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem 275: 19439-19442, 2000.
115. Lambert MP, Barlow AK, Chromy BA et Al: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453, 1998.
116. Hartley DM, Walsh DM, Ye CP et Al: Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884, 1999.
117. Hsia AY, Masliah E, McConlogue L et Al: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-3233, 1999.
118. Mucke L, Masliah E, Yu GQ et Al: High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058, 2000.
119. Selkoe DJ: The early diagnosis of Alzheimer's disease, in The pathophysiology of Alzheimer's disease, Scinto LFM and Daffner KR, Editors. Humana: Totowa, NJ 2000: 83-104.
120. Barrow CJ: Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease. Drug News Perspect 15: 102-109, 2002.
121. Auld DS, Kornecook TJ, Bastianetto S et Al: Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68: 209-245, 2002.
122. Bowen DM, Palmer AM, Frances PT et Al: Classical neurotransmitters in Alzheimer's disease, in Aging and the Brain, Terry RD, Editor. Raven Press: New York 1988: 115-128.
123. Emilien G, Beyreuther K, Masters CL et Al: Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 57: 454-459, 2000.
124. Mobius HJ: Memantine: update on the current evidence. Int J Geriatr Psychiatry 18: 47-54, 2003.
125. Winblad B, Jelic V: Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry 18: S41-46, 2003.
126. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9: 275-308, 2003.
127. Reisberg B, Doody R, Stoffler A et Al: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341, 2003.
128. Moosmann B, Behl C: Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 11: 1407-1435, 2002.
129. Sano M, Ernesto C, Thomas RG et Al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336: 1216-1222, 1997.
130. Bano S, Parihar MS: Reduction of lipid peroxidation in different brain regions by a combination of alpha-tocopherol and ascorbic acid. J Neural Transm 104: 1277-1286, 1997.
131. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 328: 176-183, 1993.
132. Spina MB, Squinto SP, Miller J et Al: Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4- phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59: 99-106, 1992.
133. Prasad KN, Hovland AR, Cole WC et Al: Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 23: 2-13, 2000.
134. Parihar MS, Hemnani T: Experimental excitotoxicity provokes oxidative damage in mice brain and attenuation by extract of Asparagus racemosus. J Neural Transm 111: 1-12, 2004.
135. Parihar MS, Hemnani T: Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci 28: 121-128, 2003.
136. Beyer RE: An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 70: 390-403, 1992.
137. Hemmer W and Wallimann T, Functional aspects of creatine kinase in brain. Dev Neurosci 15: 249-260, 1993.
138. Byrne E: Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders? J Clin Neurosci 9: 497-501, 2002.
139. Mendoza-Ramirez JL, Beltran-Parrazal L, Verdugo-Diaz L et Al: Delay in manifestations of aging by grafting NGF cultured chromaffin cells in adulthood. Neurobiol Aging 16: 907-916, 1995.
140. Behl C, Holsboer F: The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci 20: 441-444, 1999.
141. Xu H, Gouras GK, Greenfield JP et Al: Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4: 447-451, 1998.
142. LeVine III H: Challenges of targeting Aβ fibrillogenesis and other protein folding disorders. Amyloid: J. Protein Folding Disord 10: 133-135, 2003.
143. Conway KA, Baxter EW, Felsenstein KM et Al: Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Des 9: 427-447, 2003.
144. Citron M: Secretases as targets for the treatment of Alzheimer's disease. Mol Med Today 6: 392-397, 2000.
145. Xia W: Amyloid inhibitors and Alzheimer's disease. Curr Opin Investig Drugs 4: 55-59, 2003.
146. Doraiswamy PM: Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 16: 811-824, 2002.
147. Maiorini AF, Gaunt MJ, Jacobsen TM et Al: Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. J Clin Pharm Ther 27: 169-183, 2002.
148. Jhee S, Shiovitz T, Crawford AW et Al: Beta-amyloid therapies in Alzheimer's disease. Expert Opin Investig Drugs 10: 593-605, 2001.
149. Cutler NR, Sramek JJ: Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 25: 27-57, 2001.
150. Zimmermann M, Gardoni F, Marcello E et Al: Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 90: 1489-1499, 2004.
151. Caccamo A, Oddo S, Billings LM et Al: M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron, 49: 671-682, 2006.
152. Haass C, De Strooper B: The presenilins in Alzheimer's disease-proteolysis holds the key. Science 286: 916-919, 1999.
153. Wong GT, Manfra D, Poulet FM et Al: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876-12882, 2004.
154. King GD, Cherian K, Turner RS: X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. J Neurochem, 88(4): p. 971-982, 2004.
155. Lanz TA, Hosley JD, Adams WJ et Al: Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl] -L-alaninamide (LY-411575). J Pharmacol Exp Ther 309: 49-55, 2004.
156. Kornilova AY, Das C, Wolfe MS: Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications. J Biol Chem 278: 16470-16473, 2003.
157. Lanz TA, Himes CS, Pallante G et Al: The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305: 864-871, 2003.
158. Takahashi Y, Hayashi I, Tominari Y et Al: Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 278: 18664-18670, 2003.
159. Wolfe MS: Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 1: 859-866, 2002.
160. Schenk D: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828, 2002.
161. McLaurin J, Cecal R, Kierstead ME et Al: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269, 2002.
162. Hock C, Konietzko U, Papassotiropoulos A et Al: Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8: 1270-1275, 2002.
163. Schenk D, Barbour R, Dunn W et Al: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999.
164. Janus C: Vaccines for Alzheimer's disease: how close are we? CNS Drugs 17: 457-474, 2003.
165. Cherny RA, Atwood CS, Xilinas ME et Al: Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676, 2001.
166. Weiner HL, Lemere CA, Maron R et Al: Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol 48: 567-579, 2000.
167. Janus C, Pearson J, McLaurin J et Al: Aβ-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982, 2000.
168. Bard F, Cannon C, Barbour R et Al: Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med 6: 916-919, 2000.
169. DeMattos RB, Bales KR, Cummins DJ et Al: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98: 8850-8855, 2001.
170. Wilcock DM, DiCarlo G, Henderson D et Al: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745-3751, 2003.
171. Robinson SR, Bishop GM, Lee HG et Al: Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25: 609-615, 2004.
172. Broytman O, Malter JS: Anti-Abeta: The good, the bad, and the unforeseen. J Neurosci Res 75: 301-306, 2004.
173. Robinson SR, Bishop GM, Munch G: Alzheimer vaccine: amyloid-beta on trial. Bioessays 25: 283-288, 2003.
174. Munch G, Robinson SR: Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J Neural Transm 109: 1081-1087, 2002.
175. Rogers J, Webster S, Lue LF et Al: Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17: 681-686, 1996.
176. Weggen S, Eriksen JL, Das P et Al: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216, 2001.
177. Beher D, Clarke EE, Wrigley JD et Al: Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma -secretase at a novel site-evidence for an allosteric mechanism. J Biol Chem 2004.
178. Lim GP, Yang F, Chu T et Al: Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22: 983-991, 2001.
179. Jantzen PT, Connor KE, DiCarlo G et Al: Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246-2254, 2002.
180. Refolo LM, Pappolla MA, LaFrancois J et Al: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899, 2001.
181. Wolozin B, Kellman W, Ruosseau P et Al: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443, 2000.
182. Jick H, Zornberg GL, Jick SS et Al: Statins and the risk of dementia. Lancet 356: 1627-1631, 2000.
183. Sparks DL, Kuo YM, Roher A et Al: Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903: 335-344, 2000.
184. Refolo LM, Malester B, LaFrancois J et Al: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331, 2000.
185. Fassbender K, Simons M, Bergmann C et Al: Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-5861, 2001.
186. Wahrle S, Das P, Nyborg AC et Al: Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9: 11-23, 2002.
187. Cherny RA, Legg JT, McLean CA et Al: Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem 274: 23223-23228, 1999.
188. Atwood CS, Huang X, Khatri A et Al: Copper catalyzed oxidation of Alzheimer Aβ. Cell. Mol. Biol 46: 777-783, 2000.
189. Huang X, Atwood CS, Hartshorn MA et Al: The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616, 1999.
190. Huang X, Cuajungco MP, Atwood CS et Al: Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem 274: 37111-37116, 1999.
191. Bush AI, Pettingell WH, Multhaup G et Al: Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265: 1464-1467, 1994.
192. Lovell MA, Robertson JD, Teesdale WJ et Al: Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158: 47-52, 1998.
193. Bush AI: Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038, 2002.
194. Padmanabhan G et Al: In. Klauss E et Al: Clioquinol. In Analytical Profiles of Drug Substances. In Analytical Profiles of Drug Substances. Academic Press: 57-90, 1989.
195. Ritchie CW, Bush AI, Mackinnon A et Al: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691, 2003.
196. Jobst KA, Smith AD, Szatmari M et Al: Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340: 1179-1183, 1992.
197. Scheltens PH: Structural neuroimaging of Alzheimer's disease and other dementias. Aging 13: 203-209, 2001.
198. O'Brien JT, Metcalfe S, Swann A et Al: Medial temporal lobe width on CT scanning in Alzheimer's disease; comparison with vascular dementia, depression and dementia with Lewy bodies. Dement. Geriatr. Cogn Disord 11: 114-118, 2000.
199. Juottonen K, Laakso MP, Insausti R et Al: Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging 19: 15-22, 1998.
200. Thompson PM, Hayashi KM, De Zubicaray GI et Al: Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 22: 1754-1766, 2004.
201. Du AT, Schuff N, Amend D et Al: Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 71(4): 441-447, 2001.
202. Wolf H, Jelic V, Gertz HJ et Al: A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 179: 52-76, 2003.
203. de Leon MJ, DeSanti S, Zinkowski R et Al: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27: 394-401, 2006.
204. Barber R, McKeith IG, Ballard C et Al: A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 12: 198-205, 2001.
205. Chetelat G, Baron JC: Early diagnosis of Alzheimer's disease; contribution of structural neuroimaging. Neuroimage 18: 525-541, 2003.
206. Scheltens P, Fox N, Barkhof F et Al: Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1: 13-21, 2002.
207. Killiany RJ, Gomez-Isla T, Moss M et Al: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 47: 430-439, 2000.
208. Killiany RJ, Hyman BT, Gomez-Isla T et Al: MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58: 1188-1196, 2002.
209. Petrella JR, Coleman RE, Doraiswamy PM: Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-336, 2003.
210. Rapoport SI: Hydrogen magnetic resonance spectroscopy in Alzheimer's disease. Lancet Neurol 1: 82, 2002.
211. Schuff N, Capizzano AA, Du AT et Al: Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58: 928-935, 2002.
212. Xu Y, Jack CRJ, O'Brien PC et Al: Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54: 1760-1767, 2000.
213. de Leon MJ, Convit A, DeSanti S et Al: Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int Psychogeriatr 9: 183-190, 247-152, 1997.
214. De Toledo-Morrell L, Goncharova I, Dickerson B et Al: From healthy aging to early Alzheimer's disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 911: 240-253, 2000.
215. Bobinski M, de Leon MJ, Convit A et Al: MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 353: 38-40, 1999.
216. Dickerson BC, Goncharova I, Sullivan MP et Al: MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 22: 747-754, 2001.
217. Silverman DH and Phelps ME: Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Mol Genet Metab 74: 128-138, 2001.
218. Villemagne VL, Rowe CC, Macfarlane S et Al: Imaginem Oblivionis: The prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci 12: 221-230, 2005.
219. Courtney SM, Ungerleider LG, Keil K et Al: Transient and sustained activity in a distributed neural system for human working memory. Nature 386: 608-611, 1997.
220. Harris GJ, Lewis RF, Satlin A et Al: Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am J Neuroradiol 19: 1727-1732, 1998.
221. Bozzao A, Floris R, Baviera ME et Al: Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. Am J Neuroradiol 22: 1030-1036, 2001.
222. Doraiswamy PM, Chen JG, Charles HC: Brain magnetic resonance spectroscopy: role in assessing outcomes in Alzheimer's disease. CNS Drugs 14: 457-472, 2000.
223. Jessen F, Block W, Traber F et Al: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55: 684-688, 2000.
224. Longo R, Giorgini A, Magnaldi S et Al: Alzheimer's disease histologically proven studied by MRI and MRS: two cases. Magn Reson Imaging 11: 1209-1215, 1993.
225. Miller EK, Li L, Desimone R: Activity of neurons in anterior inferior temporal cortex during a short-term memory task. J Neurosci 13: 1460-1478, 1993.
226. Frederick BB, Satlin A, Yurgelun-Todd DA et Al: In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry 42: 147-150, 1997.
227. Klunk WE, Panchalingam K, Moossy J et Al: Acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 42: 1578-1585, 1992.
228. Mohanakrishnan P, Fowler AH, Vonsattel JP et Al: An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 102: 503-510, 1995.
229. Satlin A, Bodick N, Offen WW et Al: Brain proton magnetic resonance spectroscopy (H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an Ml selective cholinergic agonist. Am J Psychiatry 154: 1459-1461, 1997.
230. Waldman AD, McConnell JR, Rai GS et Al: Brain MR spectroscopy at 1.0 tesla. Br J Radiol 70: 867, 1997.
231. Kantarci K, Jack CR, Xu YC et Al: Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219: 101-107, 2001.
232. Rose SE, Chen F, Chalk JB et Al: Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 69: 528-530, 2000.
233. Phelps ME: PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41: 661-681, 2000.
234. Camargo EE: Brain SPECT in neurology and psychiatry. J Nucl Med 42: 611-623, 2001.
235. Van Heertum RL, Tikofsky RS: Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 33: 77-85, 2003.
236. Salmon E, Sadzot B, Maquet P et Al: Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 35: 391-398, 1994.
237. Knopman DS, DeKosky ST, Cummings JL et Al: Practice parameter: Diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1143-1153, 2001.
238. Doody RS, Stevens JC, Beck C et Al: Practice parameter: management of dementia (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154-1166, 2001.
239. Silverman DH, Chang CY, Cummings JL et Al: Prognostic value of regional brain metabolism in evaluation of dementia. J Nucl Med 40: 71, 1999.
240. Chang CY, Silverman DH: Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev Mol Diagn 4: 63-69, 2004.
241. Silverman DH, Gambhir SS, Huang HW et Al: Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 43: 253-266, 2002.
242. Silverman DH, Small GW, Chang CY et Al: Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286: 2120-2127, 2001.
243. Devanand DP, Jacobs DM, Tang MX et Al: The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54: 257-263, 1997.
244. Coleman RE: Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 15: 837-846, x, 2005.
245. Silverman DH, Cummings JL, Small G et Al: Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4: 283-2893, 2002.
246. Kennedy AM, Frackowiak RS, Newman SK et Al: Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 186: 17-20, 1995.
247. Small GW, Mazziotta JC, Collins MT et Al: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273: 942-947, 1995.
248. Drzezga A, Lautenschlager N, Siebner H et Al: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30: 1104-1113, 2003.
249. Talbot PR, Lloyd JJ, Snowden JS et Al: A clinical role for 99mTc- HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 64: 306-313, 1998.
250. Charpentier P, Lavenu I, Defebvre L et Al: Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to Tc Hm-PAO SPECT data. J Neurol Neurosurg Psychiatry 69: 661-663, 2000.
251. Sjogren M, Gustafson L, Wikkelso C et Al: Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBFSPET ratio. Dement Geriatr Cogn Disord 11: 275-285, 2000.
252. Ishii K, Yamaji S, Kitagaki H et Al: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 53: 413-416, 1999.
253. Lobotesis K, Fenwick JD, Phipps A et Al: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56: 643-649, 2001.
254. Jobst KA, Barnetson LP, Shepstone BJ: Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria. SPECT, x-ray CT, and Apo E4 in medial temporal lobe dementias: Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 10: 271-302, 1998.
255. McKelvey R, Bergman H, Stern J et Al: Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 26: 23-28, 1999.
256. Johnson KA, Jones K, Holman BL et Al: Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50: 1563-1571, 1998.
257. Johnson KA, Lopera F, Jones K et Al: Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 56: 1545-1551, 2001.
258. Villemagne VL, Musachio JL, Scheffel U et Al: Nicotine and Related Compounds as PET and SPECT Ligands. In Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities., John Wiley & Sons. New York: 235-250, 1998.
259. Nordberg A, Hartvig P, Lilja A et Al: Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography. Acta Radiol Suppl 376: 165-166, 1991.
260. Volkow ND, Ding YS, Fowler JS et Al: Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 49: 211-220, 2001.
261. Sihver W, Langstrom B, Nordberg A: Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl 176: 27-33, 2000.
262. Villemagne VL, Horti A, Scheffel U et Al: Imaging Nicotinic Acetylcholine Receptors with PET and [F-18]-FPH, a [F-18]-Labeled Analog of Epibatidine. J Nucl Med 38: 1737-1741, 1997.
263. Musachio JL, Villemagne VL, Scheffel U et Al: [125/123I]IPH: A Radioiodinated Analog of Epibatidine for In Vivo Studies of Nicotinic Acetylcholine Receptors. Synapse 26: 392-399, 1997.
264. Musachio JL, Villemagne VL, Scheffel UA et Al: Synthesis of an 1-123 Analog of A-85380 and Preliminary SPECT Imaging of Nicotinic Receptors in Baboon. Nucl Med Biol 26: 201-207, 1999.
265. Nordberg A: In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann N Y Acad Sc 695: 27-33, 1993.
266. Nordberg A: Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 57: 215-224, 1993.
267. Nordberg A, Amberla K, Shigeta M et Al: Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12: 228-237, 1998.
268. Nordberg A, Lundqvist H, Hartvig P et Al: Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 8: 78-84, 1997.
269. Nordberg A: Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta Neurol Scand Suppl 149: 62-65, 1993.
270. Sedvall G, Nyback H, Farde L et Al: Neurotransmitter receptor imaging in Alzheimer's disease. J Neural Transm Suppl 24: 43-48, 1987.
271. Higuchi M, Yanai K, Okamura N et Al: Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99: 721-729, 2000.
272. Small GW: Neuroimaging as a diagnostic tool in dementia with Lewy bodies. Dement Geriatr Cogn Disord 17: 25-31, 2004.
273. Walker Z, Costa DC, Walker RW et Al: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73: 134-140, 2002.
274. Kemppainen N, Ruottinen H, Nagren K, et al., PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55: 205-209, 2000.
275. Kepe V, Barrio JR, Huang SC et Al: Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 103: 702-707, 2006.
276. Versijpt J, Van Laere KJ, Dumont F et Al: Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging 24: 553-561, 2003.
277. Cohen RM, Andreason PJ, Doudet DJ et Al: Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J Neurol Sci 148: 171-180, 1997.
278. Brown DR, Wyper DJ, Owens J et Al: 123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. J Psychiatr Res 31: 605-619, 1997.
279. Piggott MA, Owens J, O'Brien J et Al: Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 25: 161-173, 2003.
280. Villemagne VL, Rowe CC, Macfarlane S et Al: Imaginem Oblivionis: The prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci, in press 2004.
281. Sair HI, Doraiswamy PM, Petrella JR: In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46: 93-104, 2004.
282. Zhang J, Yarowsky P, Gordon MN et Al: Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med 51: 452-457, 2004.
283. Benveniste H, Einstein G, Kim KR et Al: Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 96: 14079-14084, 1999.
284. Higuchi M, Iwata N, Matsuba Y et Al: (19)F and (1)H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 8: 527-533, 2005.
285. Sato K, Higuchi M, Iwata N et Al: Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem 39: 573-578, 2004.
286. Okamura N, Suemoto T, Furumoto S et Al: Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25: 10857-10862, 2005.
287. Kung MP, Hou C, Zhuang ZP et Al: IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res Bull 956: 202-210, 2002.
288. Ono M, Wilson A, Nobrega J et Al: 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol, 30: 565-571, 2003.
289. Kung MP, Skovronsky DM, Hou C et Al: Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. J Mol Neurosci 20: 15-24, 2003.
290. Link CD, Johnson CJ, Fonte V et Al: Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22: 217-226, 2001.
291. Klunk WE, Bacskai BJ, Mathis CA et Al: Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropath Exp Neurol 61: 797-805, 2002.
292. Zhuang ZP, Kung MP, Hou C et Al: IBOX(2-(4'-dimethylaminophenyl)-6- iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol 28: 887-894, 2001.
293. Lee CW, Zhuang ZP, Kung MP, et al., Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain. J Med Chem 44: 2270-2275, 2001.
294. Klunk WE, Wang Y, Huang GF, et al., The binding of 2-(4'- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23: 2086-2092, 2003.
295. Klunk WE, Wang Y, Huang GF et Al: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69: 1471-1484, 2001.
296. Mathis CA, Bacskai BJ, Rajdasz ST et Al: A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12: 295-298, 2002.
297. Bacskai BJ, Hickey GA, Skoch J et Al: Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100: 12462-12467, 2003.
298. Mathis CA, Holt DP, Wang Y et Al: Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. J. Labelled Cpd. Radiopharm 44: S26-S28, 2001.
299. Mathis CA, Wang Y, Holt DP et Al: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754, 2003.
300. Klunk WE, Engler H, Nordberg A et Al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319, 2004.
301. Skovronsky DM, Zhang B, Kung MP et Al: In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97: 7609-7614, 2000.
302. Kung HF, Lee CW, Zhuang ZP et Al: Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123: 740-12741, 2001.
303. Shimadzu H, Suemoto T, Suzuki M et Al: A novel probe for imaging amyloid-b: Synthesis of F-18 labelled BF-108, an Acridine Orange analog. J Label Compd Radiopharm 46: 765-772, 2003.
304. Zhang W, Oya S, Kung MP et Al: F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 32: 799-809, 2005.
305. Kung MP, Hou C, Zhuang ZP et Al: Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 1025: 98-105, 2004.
306. Agdeppa ED, Kepe V, Petri A et Al: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18 )F]fluoroethyl)(methyl)amino]-2-naphthyl] ethylidene) malononitrile. Neuroscience 117: 723-730, 2003.
307. Agdeppa ED, Kepe V, Liu J et Al: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci 21: RC189, 2001.
308. Barrio JR, Huang SC, Cole G et Al: PET imaging of tangles and plaques in Alzheimer disease with a highly lipophilic probe. J Labelled Compd Radiopharm 42: S194-S195, 1999.
309. Shoghi-Jadid R, Small GW, Agdeppa ED et Al: Localisation of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Ger Psychiatry 10: 24-35, 2002.
310. Agdeppa ED, Kepe V, Shoghi-Jadid R et Al: In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study. J Nucl Med 42: 65P, 2001.
311. Small GW, Agdeppa ED, Kepe V et Al: In vivo brain imaging of tangle burden in humans. J Mol Neurosci 19: 323-327, 2002.
312. Lee VM: Related Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging 23: 1039-1042, 2002.
313. Marshall JR, Stimson ER, Ghilardi JR et Al: Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug Chem 13: 276-284, 2002.
314. Friedland RP, Shi J, Lamanna JC et Al: Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann N Y Acad Sci 903: 123-128, 2000.
315. Ghilardi JR, Catton M, Stimson ER et Al: Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 7: 2607-2611, 1996.
316. Kurihara A, Pardridge WM: Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111) In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug Chem 11: 380-386, 2000.
317. Saito Y, Buciak J, Yang J et Al: Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci USA 92: 10227-10231, 1995.
318. Majocha RE, Reno JM, Friedland RP et Al: Development of a monoclonal antibody specific for β/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 33: 2184-2189, 1992
319. Walker LC, Price DL, Voytko ML et Al: Labelling of cerebral amyloid in vivo with a monoclonal antibody, J Neuropathol Exp Neurol 53: 377-383, 1994.
320. Shi J, Perry G, Berridge MS et Al: Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43: 1044-1051, 2002.
321. Wadghiri YZ, Sigurdsson EM, Wisniewski T et Al: Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol 299: 365-379, 2005.
322. Vanhoutte G, Dewachter I, Borghgraef P et Al: Non-invasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med 53: 607-613, 2005.
323. Wadghiri YZ, Sigurdsson EM, Sadowski M et Al: Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50: 293-302, 2003.
324. Falangola MF, Lee SP, Nixon RA et Al: Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 30: 201-205, 2005.
325. Mathis CA, Klunk WE, Price JC et Al: Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62: 196-200, 2005.
326. Ye L, Morgenstern JL, Gee AD et Al: Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280: 23599-23604, 2005.
327. Lockhart A, Ye L, Judd DB et Al: Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280: 7677-7684, 2005.
328. Toyama H, Ye D, Ichise M et Al: PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32: 593-600, 2005.
329. Klunk WE, Engler H, Nordberg A et Al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319, 2004.
330. Verhoeff NP, Wilson AA, Takeshita S et Al: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584-595, 2004.
331. Price JC, Klunk WE, Lopresti BJ et Al: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005.
332. Buckner RL, Snyder AZ, Shannon BJ et Al: Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709-7717, 2005.
333. Villemagne VL, Ackermann U, Gong SJ et Al: Abeta amyloid imaging in dementia with Lewy bodies and Alzheimer's disease with 11C-PIB PET. J Nucl Med 46: 124P, 2005.
334. Price JL, Morris JC: Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368, 1999.
335. Hulette CM, Welsh-Bohmer KA, Murray MG et Al: Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57: 1168-1174, 1998.
336. Morris JC, Price AL: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17: 101-118, 2001.
337. Morris JC, Storandt M, Miller JP et Al: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405, 2001.
338. Braak H, Braak E: Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 9: 257-261, 269-272, 1997.
339. Thal DR, Rub U, Orantes M et Al: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800, 2002.
340. Wu C, Pike VW, Wang Y: Amyloid imaging: from benchtop to bedside. Curr Top Dev Biol 70: 171-213, 2005.
341. Nichols L, Pike VW, Cai L et Al: Imaging and In Vivo Quantitation of beta-Amyloid: An Exemplary Biomarker for Alzheimer's Disease? Biol Psychiatry 2006.
342. Schenk D, Hagen M, Seubert P: Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16: 599-606, 2004.
343. Alzheimer A: Uber eine eijenartige Erkrankung der Hirnride. Allg Z Psychiatr 64: 146-148, 1907.